Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

NCT00059787 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

NIH

Sponsor class

Conditions

Brenner Tumor
Fallopian Tube Cancer
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma
Ovarian Undifferentiated Adenocarcinoma
Stage III Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer

Interventions

DRUG: paclitaxel
DRUG: carboplatin
DRUG: erlotinib

Sponsor

National Cancer Institute (NCI)